The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?

atebimetinib (IMM-1-104) - Immuneering

setidegrasib (ASP3082) - Astellas

HRS-4642 - Jiangsu Hengrui Pharma

Rasonque (daraxonrasib) - Revolution Medicines

INCB161734 - Incyte

http://www.ncbi.nlm.nih.gov/pubmed/42663603

Christoph Sippel; Dirk Arnold; Eric Van Cutsem; Klaus Fenchel; Volker Heinemann; Wolfram C M Dempke

Aug 29, 2026